Skip to main content

Advertisement

SpringerLink
Log in

Patient-Reported Outcomes in Myelodysplastic Syndromes: the Move from Life Span to Health Span

  • Stem Cell Transplantation (R Maziarz, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The lack of fully effective therapies to alter the natural course of myelodysplastic syndromes (MDS) leads to chronic morbidity, mortality and affects quality of life (QoL). Since existing therapies outside of hematopoietic cell transplantation (HCT) are not curative, there is a growing interest in incorporating patient-reported outcomes (PROs) as meaningful endpoints for these patients in research and clinical practice.

Recent Findings

Currently, there are limited numbers of studies reporting the impact of MDS therapeutics on PROs to guide clinical decision-making and increase patient satisfaction. However, clinical trials that have incorporated QoL outcomes have demonstrated positive results with the use of growth factors, hypomethylating agents, and lenalidomide.

Summary

Here we review and highlight the importance of harnessing the power of PROs as part of a comprehensive efficacy evaluation to ultimately deliver superior patient-centered care across the spectrum of MDS. As our understanding of MDS continues to increase, adapting the metrics of these outcome measurements will be equally important as the alteration of the natural history in developing new therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Health USDo, Human Services FDACfDE, Research, Health USDo, Human Services FDACfBE, Research, et al. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.

    Article  Google Scholar 

  2. Xiao C, Polomano R, Bruner DW. Comparison between patient-reported and clinician-observed symptoms in oncology. Cancer Nurs. 2013;36(6):E1–E16.

    Article  PubMed  Google Scholar 

  3. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22(17):3485–90.

    Article  PubMed  Google Scholar 

  4. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624–32.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21(7):1159–64.

    Article  PubMed  Google Scholar 

  6. Baratelli, C., Turco, C.G.C., Lacidogna, G. et al. The role of patient-reported outcomes in outpatients receiving active anti-cancer treatment: impact on patients’ quality of life. Support Care Cancer27, 4697–4704 (2019). https://doi.org/10.1007/s00520-019-04777-2.

  7. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22(4):714–24.

    Article  PubMed  Google Scholar 

  8. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine Cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557–65.

    Article  CAS  PubMed  Google Scholar 

  9. Kotronoulas G, Kearney N, Maguire R, Harrow A, Di Domenico D, Croy S, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014;32(14):1480–501.

    Article  PubMed  Google Scholar 

  10. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes. 2009;7:102.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197–8.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Basch E, Geoghegan C, Coons SJ, Gnanasakthy A, Slagle AF, Papadopoulos EJ, et al. Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the Food and Drug Administration, and the patient. JAMA Oncol. 2015;1(3):375–9.

    Article  PubMed  Google Scholar 

  13. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31(10):1285–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Rock EP, Kennedy DL, Furness MH, Pierce WF, Pazdur R, Burke LB. Patient-reported outcomes supporting anticancer product approvals. J Clin Oncol. 2007;25(32):5094–9.

    Article  CAS  PubMed  Google Scholar 

  16. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814–22.

    Article  CAS  PubMed  Google Scholar 

  17. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006;81(1):104–30.

    Article  PubMed  Google Scholar 

  18. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med. 2005;56:1–16.

    Article  CAS  PubMed  Google Scholar 

  19. Sekeres MA. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J Natl Compr Cancer Netw. 2011;9(1):57–63.

    Article  Google Scholar 

  20. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82(2):358–67.

    Article  CAS  PubMed  Google Scholar 

  21. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–42.

    Article  PubMed  Google Scholar 

  22. Foran JM, Shammo JM. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes. Am J Med. 2012;125(7 Suppl):S6–13.

    Article  PubMed  Google Scholar 

  23. Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008;32(5):691–8.

    Article  PubMed  Google Scholar 

  24. Nguyen PL. The myelodysplastic syndromes. Hematol Oncol Clin North Am. 2009;23(4):675–91.

    Article  PubMed  Google Scholar 

  25. Cleeland CS, Williams LA. Symptom burden in hematologic malignancies. Blood. 2014;123(24):3686–7.

    Article  CAS  PubMed  Google Scholar 

  26. Thomas ML. Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. Leuk Res. 1998;22(Suppl 1):S41–7.

    Article  PubMed  Google Scholar 

  27. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–88.

    Article  CAS  PubMed  Google Scholar 

  28. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sekeres MA, Gerds AT. Established and novel agents for myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2014;2014(1):82–9.

    Article  PubMed  Google Scholar 

  30. Martino R, Valcarcel D, Brunet S, Sureda A, Sierra J. Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant. 2008;41(1):33–8.

    Article  CAS  PubMed  Google Scholar 

  31. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007;110(4):1379–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008;14(2):246–55.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Deeg HJ. Transplant strategies for patients with myelodysplastic syndromes. Curr Opin Hematol. 2006;13(2):61–6.

    Article  PubMed  Google Scholar 

  34. Deeg HJ. Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS). Hematology Am Soc Hematol Educ Program. 2005:167–73.

  35. El-Jawahri A, Kim HT, Steensma DP, Cronin AM, Stone RM, Watts CD, et al. Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transplant. 2016;51(8):1121–6.

    Article  CAS  PubMed  Google Scholar 

  36. Sekeres MA, Steensma DP. Rethinking clinical trial endpoints in myelodysplastic syndromes. Leukemia. 2019;33(3):570–5.

    Article  CAS  PubMed  Google Scholar 

  37. Cannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, Efficace F. Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: what have we learned? Crit Rev Oncol Hematol. 2015;96(3):542–54.

    Article  PubMed  Google Scholar 

  38. Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, et al. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica. 2016;101(6):781–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. A basket study of novel therapy for untreated MDS/MPN and relapsed/refractory overlap syndromes (ABNL-MARRO). https://ClinicalTrials.gov/show/NCT04061421.

  40. Interventional validation of an MDS-specific measure of quality of life: assessing the responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to different hypomethylating agent regimens for low and intermediate risk disease. https://ClinicalTrials.gov/show/NCT02378701.

  41. Phase II Decitabine (DAC) versus azacitidine (AZA) in myelodysplastic syndrome (MDS). https://ClinicalTrials.gov/show/NCT02269280.

  42. Cottone F, Efficace F, Sommer K, Caocci G, Fazi P, Vignetti M, et al. Validation of the EORTC QLQ-C30 Summary Score in patients with hematological malignancies. 2019;37(15_suppl):e18551-e.

  43. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2):13–9.

    CAS  PubMed  Google Scholar 

  44. Platzbecker U, Hofbauer LC, Ehninger G, Holig K. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res. 2012;36(5):525–36.

    Article  PubMed  Google Scholar 

  45. Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, et al. What are RBC-transfusion-dependence and -independence? Leuk Res. 2011;35(1):8–11.

    Article  CAS  PubMed  Google Scholar 

  46. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503–10.

    Article  PubMed  Google Scholar 

  47. Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2003;121(2):270–4.

    Article  CAS  PubMed  Google Scholar 

  48. Lucioni C, Finelli C, Mazzi S, Oliva EN. Costs and quality of life in patients with myelodysplastic syndromes. Am J Blood Res. 2013;3(3):246–59.

    PubMed  PubMed Central  Google Scholar 

  49. Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira BC, et al. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. Br J Haematol. 2019;184(2):134–60.

    Article  CAS  PubMed  Google Scholar 

  50. Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109(9):1705–14.

    Article  CAS  PubMed  Google Scholar 

  51. Prica A, Sholzberg M, Buckstein R. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. Br J Haematol. 2014;167(5):626–38.

    Article  CAS  PubMed  Google Scholar 

  52. Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;4(3):e127–e36.

    Article  PubMed  Google Scholar 

  53. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–40.

    Article  CAS  PubMed  Google Scholar 

  54. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794–803.

    Article  CAS  PubMed  Google Scholar 

  55. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765–76.

    Article  CAS  PubMed  Google Scholar 

  56. Santini V, Almeida A, Giagounidis A, Gropper S, Jonasova A, Vey N, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34(25):2988–96.

    Article  CAS  PubMed  Google Scholar 

  57. Santini V, Almeida A, Giagounidis A, Platzbecker U, Buckstein R, Beach CL, et al. The effect of lenalidomide on health-related quality of life in patients with lower-risk non-del(5q) myelodysplastic syndromes: results from the MDS-005 study. Clin Lymphoma Myeloma Leuk. 2018;18(2):136–44 e7.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Shimoli V. Barot, Bhumika J. Patel and Aaron T. Gerds contributed equally to this work.

Authors and Affiliations

  1. Department of Internal Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    Shimoli V. Barot

  2. Department of Leukemia, Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, CA-6, Cleveland, OH, 44195, USA

    Bhumika J. Patel & Aaron T. Gerds

Authors
  1. Shimoli V. Barot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bhumika J. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aaron T. Gerds
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bhumika J. Patel.

Ethics declarations

Conflict of Interest

Shimoli V. Barot and Bhumika J. Patel declare no conflicts of interest. Aaron T. Gerds: Celgene, Incyte, Pfizer, Kartos, Apexx Oncology.

Human and Animal Rights and Informed Consent

This article contains no studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Stem Cell Transplantation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barot, S.V., Patel, B.J. & Gerds, A.T. Patient-Reported Outcomes in Myelodysplastic Syndromes: the Move from Life Span to Health Span. Curr Hematol Malig Rep 15, 149–154 (2020). https://doi.org/10.1007/s11899-020-00562-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-020-00562-9

Keywords

Search

Navigation